Lisata Therapeutics Inc Financials
Lisata Therapeutics Inc (LSTA) reported $170K in revenue for fiscal year 2025, down 83.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lisata’s model is still cash-funded drug development, with narrower losses driven more by spending cuts than revenue formation.
In both FY2024 and FY2025, net loss and operating cash burn tracked closely, landing near$20.0M and then near$16.0M . That makes the deficit real cash consumption rather than mainly accounting noise, so year-end cash of$16.0M covered only about one year of the latest burn rate.
Revenue is still incidental: FY2025 revenue was only
The balance sheet is not debt-driven: cash of
Financial Health Signals
Lisata Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Lisata Therapeutics Inc scores -44.27, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.0M) relative to total liabilities ($3.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Lisata Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Lisata Therapeutics Inc reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Lisata Therapeutics Inc generated $170K in revenue in fiscal year 2025. This represents a decrease of 83.0% from the prior year.
Lisata Therapeutics Inc's EBITDA was -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.8% from the prior year.
Lisata Therapeutics Inc reported -$16.6M in net income in fiscal year 2025. This represents an increase of 17.0% from the prior year.
Lisata Therapeutics Inc earned -$1.91 per diluted share (EPS) in fiscal year 2025. This represents an increase of 20.4% from the prior year.
Cash & Balance Sheet
Lisata Therapeutics Inc recorded an outflow of $16.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 17.5% from the prior year.
Lisata Therapeutics Inc held $16.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Lisata Therapeutics Inc's ROE was -111.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 44.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Lisata Therapeutics Inc invested $7.9M in research and development in fiscal year 2025. This represents a decrease of 29.9% from the prior year.
Lisata Therapeutics Inc invested $28K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
LSTA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $170K-83.0% | $1.0M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | $35.3M+56.9% | $22.5M+25.4% | $17.9M+22.3% | $14.7M+2.4% | $14.3M+42.6% | $10.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $31.1M+54.5% | $20.2M+28.6% | $15.7M+21.1% | $12.9M+8.4% | $11.9M+38.2% | $8.6M |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.1M+78.1% | $2.3M+3.0% | $2.3M+31.3% | $1.7M-27.7% | $2.4M+69.6% | $1.4M |
| R&D Expenses | N/A | $7.9M-29.9% | $11.3M-11.0% | $12.7M-2.5% | $13.1M-26.1% | $17.7M+91.1% | $9.3M-14.3% | $10.8M+42.2% | $7.6M-52.1% | $15.8M-5.1% | $16.7M-30.1% | $23.9M-18.1% | $29.2M+72.6% | $16.9M+61.9% | $10.5M+35.4% | $7.7M |
| SG&A Expenses | N/A | $10.4M-13.6% | $12.1M-6.9% | $13.0M-8.3% | $14.1M+23.2% | $11.5M+16.0% | $9.9M+6.4% | $9.3M-1.0% | $9.4M-20.1% | $11.8M-8.2% | $12.8M-57.3% | $30.0M-2.6% | $30.8M+42.5% | $21.6M-3.1% | $22.3M-19.4% | $27.7M |
| Operating Income | N/A | -$18.2M+18.7% | -$22.4M+12.8% | -$25.7M+55.4% | -$57.6M-98.3% | -$29.1M-51.7% | -$19.1M+4.7% | -$20.1M-18.3% | -$17.0M+38.4% | -$27.6M+6.5% | -$29.5M+74.1% | -$113.8M-97.2% | -$57.7M-56.9% | -$36.8M-21.1% | -$30.4M+10.6% | -$34.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $5K-98.7% | $378K-78.8% | $1.8M-16.4% | $2.1M+181.7% | $756K+168.5% | $281K-82.2% | $1.6M-40.4% | $2.6M |
| Income Tax | N/A | -$962K-20.6% | -$798K+65.8% | -$2.3M+6.0% | -$2.5M-64.4% | -$1.5M+86.1% | -$10.9M | $0 | $0+100.0% | -$11.5M | $0+100.0% | -$17.2M-16448.2% | -$104K-113.4% | $780K+544.4% | -$176K | $0 |
| Net Income | N/A | -$16.6M+17.0% | -$20.0M+4.1% | -$20.8M+61.6% | -$54.2M-97.4% | -$27.5M-237.0% | -$8.2M+57.9% | -$19.4M-19.8% | -$16.2M-170.4% | $23.0M+170.4% | -$32.7M+59.7% | -$81.0M-47.6% | -$54.9M-40.8% | -$39.0M+27.5% | -$53.8M-14.1% | -$47.1M |
| EPS (Diluted) | — | -$1.91+20.4% | -$2.40+7.0% | -$2.58 | -$10.47 | -$7.45 | -$0.53 | N/A | N/A | $2.56+151.3% | -$4.99 | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LSTA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.7M-49.3% | $35.0M-36.0% | $54.7M-25.1% | $73.0M-24.7% | $97.0M+169.5% | $36.0M+32.6% | $27.2M-39.1% | $44.6M-29.7% | $63.4M+18.4% | $53.5M-6.5% | $57.2M-54.7% | $126.3M+40.6% | $89.8M+65.1% | $54.4M-65.0% | $155.3M |
| Current Assets | $17.7M-48.8% | $34.6M-35.9% | $53.9M-25.0% | $71.9M-25.3% | $96.2M+172.2% | $35.3M+36.0% | $26.0M-41.1% | $44.1M-28.2% | $61.4M+149.1% | $24.6M-15.8% | $29.3M-19.3% | $36.3M-28.6% | $50.8M+204.2% | $16.7M-56.7% | $38.6M |
| Cash & Equivalents | $16.0M-1.6% | $16.2M-28.3% | $22.6M-29.7% | $32.2M+30.5% | $24.6M+49.3% | $16.5M+17.7% | $14.0M+36.2% | $10.3M-64.7% | $29.2M+312.1% | $7.1M-62.1% | $18.7M-2.7% | $19.2M-58.4% | $46.1M+235.8% | $13.7M+249.1% | $3.9M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.3M+14.1% | $1.1M+71.8% | $648K |
| Accounts Receivable | $0-100.0% | $900K | $0 | N/A | N/A | N/A | N/A | N/A | $234K+69.0% | $139K-94.6% | $2.6M-17.5% | $3.1M+67.2% | $1.9M+76.6% | $1.1M+4.3% | $1.0M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $7.0M0.0% | $7.0M-72.2% | $25.2M+126.7% | $11.1M0.0% | $11.1M0.0% | $11.1M |
| Total Liabilities | $3.1M-44.7% | $5.7M-16.4% | $6.8M+1.3% | $6.7M+34.0% | $5.0M+33.2% | $3.8M-43.0% | $6.6M-7.4% | $7.1M-46.0% | $13.2M-72.9% | $48.6M+43.4% | $33.9M-50.3% | $68.2M+145.4% | $27.8M+30.9% | $21.2M-77.2% | $93.3M |
| Current Liabilities | $3.1M-45.3% | $5.6M-14.8% | $6.6M+3.2% | $6.4M+41.1% | $4.5M+29.0% | $3.5M-41.3% | $6.0M+6.4% | $5.6M-39.7% | $9.3M-56.0% | $21.2M+0.8% | $21.0M+29.4% | $16.2M+65.6% | $9.8M-1.4% | $9.9M-72.7% | $36.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $2.5M-76.7% | $10.8M-22.0% | $13.9M | $0 | $0 | N/A |
| Total Equity | $14.9M-49.8% | $29.6M-38.6% | $48.1M-27.7% | $66.6M-27.8% | $92.3M+183.9% | $32.5M+56.1% | $20.8M-44.8% | $37.7M-25.3% | $50.5M+934.2% | $4.9M-79.4% | $23.7M-59.5% | $58.5M-6.4% | $62.5M+88.5% | $33.2M-46.5% | $62.0M |
| Retained Earnings | -$564.7M-3.0% | -$548.1M-3.8% | -$528.1M-4.1% | -$507.2M-12.0% | -$453.0M-6.5% | -$425.6M-2.0% | -$417.4M-4.9% | -$398.0M-4.2% | -$381.8M+5.7% | -$404.8M-8.8% | -$372.1M-27.8% | -$291.2M-23.2% | -$236.4M-19.7% | -$197.4M-37.9% | -$143.1M |
LSTA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.3M | -$15.9M+17.6% | -$19.4M+3.4% | -$20.0M+5.4% | -$21.2M+4.8% | -$22.2M-152.1% | -$8.8M+53.3% | -$18.9M+5.5% | -$20.0M+4.3% | -$20.9M+11.8% | -$23.7M+39.7% | -$39.3M+16.3% | -$46.9M-73.0% | -$27.1M-95.6% | -$13.9M+33.8% | -$20.9M |
| Capital Expenditures | $0 | $28K | $0 | $0-100.0% | $285K+375.0% | $60K+200.0% | $20K | $0-100.0% | $134K-0.7% | $135K-87.7% | $1.1M-65.5% | $3.2M-12.9% | $3.7M+35.9% | $2.7M+406.6% | $531K-7.6% | $575K |
| Free Cash Flow | -$12.3M | -$16.0M+17.5% | -$19.4M+3.4% | -$20.0M+6.6% | -$21.5M+3.8% | -$22.3M-152.2% | -$8.8M+53.2% | -$18.9M+6.2% | -$20.1M+4.2% | -$21.0M+15.2% | -$24.8M+41.6% | -$42.4M+16.0% | -$50.6M-69.7% | -$29.8M-107.1% | -$14.4M+33.1% | -$21.5M |
| Investing Cash Flow | $5.2M | $15.1M+14.0% | $13.2M+31.0% | $10.1M-65.1% | $28.9M+152.7% | -$54.9M-654.4% | -$7.3M-134.0% | $21.4M+555.3% | -$4.7M-111.4% | $41.3M+1548.5% | -$2.8M-175.0% | $3.8M+135.4% | -$10.7M-298.9% | -$2.7M-144.2% | $6.1M+396.3% | -$2.1M |
| Financing Cash Flow | $768K | $599K+390.8% | -$206K-153.5% | $385K+271.9% | -$224K-100.3% | $85.3M+359.0% | $18.6M+1470.6% | $1.2M+43.6% | $824K+188.4% | -$932K-104.5% | $20.9M-42.9% | $36.6M+19.3% | $30.7M-50.7% | $62.2M+611.4% | $8.7M-56.4% | $20.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $328K | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
LSTA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 11.8%+1.4pp | 10.4%-2.2pp | 12.6%+0.9pp | 11.7%-4.9pp | 16.6%+2.6pp | 14.0% |
| Operating Margin | -10711.2% | -2240.9% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -83.6% | -506.3% | -321.9% | -250.9% | -212.0% | -338.4% |
| Net Margin | -9756.5% | -1998.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -92.5% | -360.3% | -305.9% | -265.8% | -375.2% | -469.0% |
| Return on Equity | -111.7%-44.1pp | -67.6%-24.3pp | -43.3%+38.2pp | -81.5%-51.7pp | -29.8%-4.7pp | -25.1%+67.9pp | -93.0%-50.2pp | -42.9%-88.3pp | 45.5%+714.1pp | -668.6%-327.0pp | -341.6%-247.8pp | -93.8%-31.4pp | -62.3%+99.7pp | -162.1%-86.1pp | -76.0% |
| Return on Assets | -93.5%-36.4pp | -57.1%-19.0pp | -38.1%+36.2pp | -74.3%-45.9pp | -28.3%-5.7pp | -22.6%+48.7pp | -71.3%-35.0pp | -36.3%-72.5pp | 36.3%+97.3pp | -61.0%+80.6pp | -141.6%-98.2pp | -43.5%-0.1pp | -43.4%+55.4pp | -98.8%-68.5pp | -30.3% |
| Current Ratio | 5.76-0.4x | 6.16-2.0x | 8.18-3.1x | 11.26-10.0x | 21.27+11.2x | 10.08+5.7x | 4.35-3.5x | 7.85+1.3x | 6.59+5.4x | 1.16-0.2x | 1.39-0.8x | 2.23-2.9x | 5.18+3.5x | 1.68+0.6x | 1.06 |
| Debt-to-Equity | 0.210.0x | 0.19+0.1x | 0.140.0x | 0.100.0x | 0.05-0.1x | 0.12-0.2x | 0.32+0.1x | 0.19+0.2x | 0.00-0.5x | 0.52+0.1x | 0.46+0.2x | 0.24+0.2x | 0.000.0x | 0.00-1.5x | 1.50 |
| FCF Margin | -9398.2% | -1935.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -70.2% | -188.7% | -281.8% | -203.1% | -100.4% | -214.0% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Lisata Therapeutics Inc Ranks
Frequently Asked Questions
What is Lisata Therapeutics Inc's annual revenue?
Lisata Therapeutics Inc (LSTA) reported $170K in total revenue for fiscal year 2025. This represents a -83.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lisata Therapeutics Inc's revenue growing?
Lisata Therapeutics Inc (LSTA) revenue declined by 83.0% year-over-year, from $1.0M to $170K in fiscal year 2025.
Is Lisata Therapeutics Inc profitable?
No, Lisata Therapeutics Inc (LSTA) reported a net income of -$16.6M in fiscal year 2025.
What is Lisata Therapeutics Inc's EBITDA?
Lisata Therapeutics Inc (LSTA) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lisata Therapeutics Inc's return on equity (ROE)?
Lisata Therapeutics Inc (LSTA) has a return on equity of -111.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lisata Therapeutics Inc's free cash flow?
Lisata Therapeutics Inc (LSTA) recorded an outflow of $16.0M in free cash flow during fiscal year 2025. This represents a 17.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lisata Therapeutics Inc's operating cash flow?
Lisata Therapeutics Inc (LSTA) recorded an outflow of $15.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Lisata Therapeutics Inc's total assets?
Lisata Therapeutics Inc (LSTA) had $17.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lisata Therapeutics Inc's capital expenditures?
Lisata Therapeutics Inc (LSTA) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lisata Therapeutics Inc spend on research and development?
Lisata Therapeutics Inc (LSTA) invested $7.9M in research and development during fiscal year 2025.
What is Lisata Therapeutics Inc's current ratio?
Lisata Therapeutics Inc (LSTA) had a current ratio of 5.76 as of fiscal year 2025, which is generally considered healthy.
What is Lisata Therapeutics Inc's debt-to-equity ratio?
Lisata Therapeutics Inc (LSTA) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lisata Therapeutics Inc's return on assets (ROA)?
Lisata Therapeutics Inc (LSTA) had a return on assets of -93.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lisata Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Lisata Therapeutics Inc (LSTA) had $16.0M in cash against an annual operating cash burn of $15.9M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Lisata Therapeutics Inc's Altman Z-Score?
Lisata Therapeutics Inc (LSTA) has an Altman Z-Score of -44.27, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Lisata Therapeutics Inc's Piotroski F-Score?
Lisata Therapeutics Inc (LSTA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lisata Therapeutics Inc's earnings high quality?
Lisata Therapeutics Inc (LSTA) reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.